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ABSTRACT: Metallonitrosyl complexes are promising as nitric
oxide (NO) donors for the treatment of cardiovascular, endothelial,
and pathogenic diseases, as well as cancer. Recently, the reduced
form of NO− (protonated as HNO, nitroxyl, azanone, isoelectronic
with O2) has also emerged as a candidate for therapeutic
applications including treatment of acute heart failure and
alcoholism. Here, we show that HNO is a product of the reaction
of the RuII complex [Ru(bpy)2(SO3)(NO)]
+ (1) with glutathione
or N-acetyl-L-cysteine, using met-myoglobin and carboxy-PTIO (2-
(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide)
as trapping agents. Characteristic absorption spectroscopic proﬁles
for HNO reactions with met-myoglobin were obtained, as well as
EPR evidence from carboxy-PTIO experiments. Importantly, the product HNO counteracted NO-induced as well as hypoxia-
induced stabilization of the tumor-suppressor HIF-1α in cancer cells. The functional disruption of neovascularization by HNO
produced by this metallonitrosyl complex was demonstrated in an in vitro angiogenesis model. This behavior is consistent with
HNO biochemistry and contrasts with NO-mediated stabilization of HIF-1α. Together, these results demonstrate for the ﬁrst
time thiol-dependent production of HNO by a ruthenium complex and subsequent destabilization of HIF-1α. This work suggests
that the complex warrants further investigation as a promising antiangiogenesis agent for the treatment of cancer.
Nitric oxide (NO) has emerged as a key biologicalsignaling molecule, and a myriad of physiological and
pathophysiological functions have now been revealed which
strongly support the medical potential for targeting NOS-
derived NO in many disease settings.1−5 More recently, the
reduced form of NO, called nitroxyl (HNO), has attracted
attention for its distinct biological activities.6 Toward this end,
HNO has promising activity in the cardiovascular system,
cancer therapy, and neuronal function.6 Importantly, HNO
exhibits many activities which are distinct from NO, including
its ability to limit the accumulation of the tumor suppressor
hypoxia-inducible factor-1 (HIF-1α). Unfortunately, there are
few well-characterized HNO donors available, in contrast to the
wide variety of NO donors.7 The available HNO donors are
mainly organic compounds. Metal-based HNO donors are
scarce even though many examples of metal complexes as NO
donors are known.
HNO is highly reactive toward thiols, while NO depends
directly on oxygen-mediated processes that cause thiol
modiﬁcation.6 Moreover, HNO exhibits a distinct pattern of
thiol modiﬁcations when compared to NO, including the
conversion of thiols to sulﬁnamides, disulﬁdes, and sulfenic
acids, instead of thiol nitrosation.6,8,9 Protein thiol modiﬁcation
has been associated with some biological activities ascribed to
HNO. Two well-described enzymatic systems, glyceraldehyde-
3-phosphate dehydrogenase (GADPH)8,10 and aldehyde
dehydrogenase, are direct targets for HNO, and other
suggested targets include cathepsin B and papain.11 These
enzymes share similar reactivity proﬁles: they are inhibited by
reaction of HNO with their functional thiols. Another target of
HNO is hypoxia-regulated transcription factor HIF-1α.
Importantly, HNO and NO show divergent regulatory eﬀects
on HIF-1α as HNO limits hypoxia- and NO-mediated HIF-1α
protein stabilization. This observation makes HNO an
attractive candidate for cancer therapy because NO and HIF-
1α mediate several signaling cascades involved in the disease
progression of cancer.12−15
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The use of ruthenium complexes in medicine has greatly
expanded, with some compounds advancing in human clinical
trials after demonstrating very low toxicity.16−18 These
important ﬁndings have motivated the scientiﬁc community
and have led to the development of a wide number of metal-
based compounds.16 Particularly, nitrosyl ruthenium complexes
(e.g., RuII−NO+) have been developed and investigated as NO
donors by many laboratories including ours.19−22 Interestingly,
these metal complexes release NO upon chemical reduction or
by light irradiation.23,24 One key strategy for NO release that
has physiological potential relies on the modulation of the
NO+/NO0 reduction process where reduction drives the
dissociation of NO. This reaction can be altered by the type
of ancillary ligand (σ-donor, π-acceptor), which controls the
electrochemical potential for bound NO as well as its bonding
strength.19 Bioreductants also show promising ability to
generate NO.23,25 We have developed a series of nitrosyl
complexes based on ruthenium bipyridine chemistry that show
promising biological activity including vasodilation activity,26
neuroprotection during ischemia/reperfusion in the brain,27
anti-Chagas disease,28 antiparacoccidioidomycosis activity,29
gastric protection,30 and analgesic eﬀects.31 Among these is
the sulﬁte complex [Ru(bpy)2(SO3)(NO)]
+ (1; Figure 1).
Interestingly, the presence of the sulﬁte ligand diﬀerentiates 1
from most nitrosyl ruthenium complexes of this type as it
modulates the acid−base equilibrium for bound NO+/NO2−,
which is only shifted toward NO2
− at higher pH (pK =
10.32).25 This property can maximize the presence of bound
NO+ at physiological pH, which might have implications for its
reactivity toward nucleophiles, particularly thiols. Also, the
electrochemical reduction potential E1/2 of −115 mV versus Ag|
AgCl is within a range accessible for biological reduction. While
the reaction with biological thiols has previously provided
qualitative evidence for NO production,23 a detailed
quantitative study has yet to be reported, including attempts
to detect other NO derivative species, e.g., HNO. Here, we
present evidence for the production of HNO triggered by the
reaction of [Ru(bpy)2(SO3)(NO)]
+ (1) complex with bio-
logical thiols and its involvement in key biological activities
involving HIF-1α.
■ RESULTS
The nitrosyl ruthenium complex stability was investigated by
monitoring changes in the electronic spectrum and the
electrochemical process at −115 mV (vs Ag|AgCl). No
signiﬁcant changes were observed in the UV−vis electronic
spectra of a 40 μM solution of [Ru(bpy)2(SO3)(NO)]
+ in 5
mM phosphate buﬀer at a pH of 7.4 and 100 mM NaCl at 37
Figure 1. Complex [Ru(bpy)2(SO3)(NO)]
+ (1) in an acid−base equilibrium, along with the electrochemical processes associated with the bound
nitrosyl moiety and free NO in solution.
Figure 2. Detection of HNO during reaction of [Ru(bpy)2(SO3)(NO)]
+ with thiols in 0.1 M phosphate buﬀer at a pH of 6.3, using (A) myoglobin
(7.8 μM) and [Ru(bpy)2(SO3)(NO)]
+ (15 μM) with reduced glutathione (200 μM), time-course spectra (inset: reaction kinetics monitored at 409
nm); (B) carboxy-PTIO (100 μM), [Ru(bpy)2(SO3)(NO)]
+ (50 μM), and N-acetylcysteine (200 μM), time-course spectra, black-line spectra
before addition of glutathione (inset: reaction kinetics monitored at 560 nm).
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°C during 12 h of incubation (Supporting Information Figure
S1A). Similarly, diﬀerential pulse voltammetry did not show
signiﬁcant electrochemical changes at −115 mV, which is
assigned to RuII−NO+/0 during 10 h of incubation (Supporting
Information Figure S1B).
Biothiol-Induced Production of Nitroxyl Species. A
well-described assay for HNO detection employs ferric-
myoglobin (met-Mb), which also distinguishes HNO from
NO.32−34 In this assay, HNO reduces met(FeIII)-myoglobin,
giving ferrous(FeII)-NO myoglobin, and a typical red shift of
the Soret band as well as changes to the Q-bands are observed.
Here, we used a slight molar excess of metallonitrosyl complex
1 to met-myoglobin to evaluate HNO production upon
reaction with glutathione (GSH, γ-L-Glu-L-Cys-Gly) or N-
acetyl-L-cysteine (NAC), a precursor of glutathione. We should
further mention that NO can eventually react with met(FeIII)-
myoglobin, but the rate is slow and aﬃnity (Kd ∼ 260 μM) very
weak, requiring much larger amounts of NO than ferrous(FeII)-
myoglobin.35,36 Additionally, FeIII−NO myoglobin shows
distinct spectroscopic features (Soret and Q-band maxima) as
compared to FeII-NO myoglobin, a result of a fast HNO
reaction.35 A series of controls were prepared to evaluate the
occurrence of any direct reaction between ferric-myoglobin and
the metallonitrosyl compound or thiols (glutathione and N-
acetyl-cysteine) alone, as well as using a standard HNO donor
(Angeli’s salt) and NO donor (DEA-NONOATE; Supporting
Information Figure S2). When this reaction was carried out
with [Ru(bpy)2(SO3)(NO)]
+ and the thiol together with met-
Mb, a typical change in the ferric myoglobin UV−vis spectra
was observed consistent with HNO production (Figure 2).
After longer incubation times, reoxidation of myoglobin was
also observed for control reactions using only the HNO donor
(Angeli’s salt) as reported elsewhere.33
The HNO probe carboxy-PTIO (cPTIO) was used to
further validate these results. Carboxy-PTIO (cPTIO) is a
stable radical well-known as a stoichiometric NO scavenger and
suitable EPR probe for the in vitro detection of NO.37 However,
this probe has notable limitations for in vivo detection of NO
due to side reactions with other biological reducing species.38
Recently, detailed studies have shown that cPTIO can be used
to distinguish NO from HNO, based on diﬀerences in the
resulting EPR signals.39 cPTIO reacts with stoichiometric
amounts of NO, yielding an increased number of EPR lines
from 5 (aN
1,3 = 8.1 G) to 7 due to the appearance of a
nonsymmetrical nitrogen leading to diﬀerent hyperﬁne splitting
constants for 14N (aN
1 = 9.8 G and aN
3 = 4.4 G).37 On the other
hand, HNO has been reported to react rapidly with
stoichiometric amounts of cPTIO leading to an EPR-silent
product (PTI).40 Electronic spectral changes are also observed
for cPTIO in reaction with HNO and NO, where a band at 560
nm equally disappears, while other changes at lower wave-
lengths can be used to distinguish them.40 Unfortunately, those
bands could not be used unequivocally in our studies due to
interference in the same range from the metal complex itself.
So, we used the band at 560 nm to assign NO or HNO
production (Figure 2), whereas the EPR signal was used to
diﬀerentiate between them (Figure 3). Similar to the reactions
with met-Mb, a series of controls were used to validate the EPR
signals and eliminate possible interferences (Supporting
Information Figures S3 and S4).
Reactions of [Ru(bpy)2(SO3)(NO)]
+ with GSH or NAC
gave rise to the rapid disappearance of the 560 nm band of
cPTIO, suggesting that NO or HNO was indeed generated
during these reactions (Figure 2). EPR spectra showed the
disappearance of the EPR signal, supporting HNO production
(Figure 3). This metal complex has been shown to photorelease
NO,25 and we veriﬁed this by EPR, observing peaks typical of
NO trapping by cPTIO (Supporting Information Figure S4).
These EPR data therefore conﬁrmed that [Ru(bpy)2(SO3)-
(NO)]+ mainly generates HNO on reaction with thiols, while
light promotes NO release. Also, we showed that reaction with
excess GSH can produce hydroxylamine, a well-described ﬁnal
product for the reaction of HNO with excess glutathione.41
Hydroxylamine was detected from reactions of both Angeli’s
salt and [Ru(bpy)2(SO3)(NO)]
+ (Supporting Information
Figure S5).
1H NMR spectra were also recorded for the reaction of
[Ru(bpy)2(SO3)(NO)]
+ with GSH at 1:0.5, 1:1, and 1:2 molar
ratios of the Ru complex to GSH. At a ratio of 1:2, the spectra
were consistent with complete production of oxidized
glutathione, which is expected for a reaction involving two-
electron transfer from thiols to generate nitroxyl from the
original nitronium reagent (Figure 1, Supporting Information
Figure S6) as described by the possible sequence of reactions
1−4.
+ → ‐ ++ +[Ru(bpy) (SO )(NO)] GSH [Ru(bpy) (SO )(NO SG)] H2 3 2 3
(1)
‐ + → ‐ ‐[Ru(bpy) (SO )(NO SG)] GSH [Ru(bpy) (SO )(NO SG HSG)]2 3 2 3
(2)
‐ ‐ → +[Ru(bpy) (SO )(NO SG HSG)] [Ru(bpy) (SO )(HNO)] GSSG2 3 2 3
(3)
+ ⇌ +[Ru(bpy) (SO )(HNO)] H O [Ru(bpy) (SO )(H O)] HNO2 3 2 2 3 2
(4)
+
⇌ + + +
+
+
[Ru(bpy) (SO )(NO)] 2GSH
[Ru(bpy) (SO )(H O)] GSSG HNO H
2 3
2 3 2
Figure 3. EPR detection of HNO using the radical carboxy-PTIO (200
μM) in 0.1 M phosphate buﬀer at a pH of 6.3, from reactions of
[Ru(bpy)2(SO3)(NO)]
+ (50 μM) with (A) N-acetyl-cysteine (800
μM) and (B) glutathione (800 μM). (C) kinetic proﬁle for EPR signal
from experiment A.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.6b00222
ACS Chem. Biol. 2016, 11, 2057−2065
2059
Electrochemical studies were also conducted for the reaction
of [Ru(bpy)2(SO3)(NO)]
+ with GSH using square-wave
voltammetry in 0.1 M phosphate buﬀer at a pH of 7.4 using
Ag|AgCl as a reference. [Ru(bpy)2(SO3)(NO)]
+ showed two
sets of signals, one at −115 mV assigned to NO+/0 processes
and another two peaks at −640 to −510 mV. The latter can be
assigned to reduction of NO0 to NO− at −510 mV and a
further reduction of NO− to NH3 at −640 mV, as reported for
other similar systems.42 These signals were greatly perturbed by
the addition of reduced glutathione (Figure 4). Almost
immediately after the addition of a 15-fold molar excess of
glutathione, the waves at −115 mV and −510 mV disappeared,
which is consistent with reaction of the NO+ ligand to give
NO−, followed by a new wave at −580 mV with a slower
change. New waves at +350 mV and +665 mV can also be
assigned to RuIII/II processes for [Ru(bpy)2(SO3)(H2O)] and
[Ru(bpy)2(SO3)(NH3)], respectively. Measurements con-
ducted with close to stoichiometric amounts of GSH (1 to
10-fold) supported fast disappearance of NO+/0 processes due
to prompt reduction of this species, along with consumption of
the signal assigned to NO0/− seen as a shoulder at −510 mV.
The main peak at very low reduction potential has been
assigned to the conversion of NO− to NH3.
42 Interestingly, this
signal was slightly aﬀected, consistent with generation of Ru-
NO−. Moreover, depending on the amount of excess
glutathione, it was possible to reach complete consumption
of NO−, which suggests an equilibrium shift may be involved.
Since an excess of glutathione can react rapidly with free HNO,
it is possible to shift the equilibrium for Ru-HNO to favor the
release of HNO, as indicated by eq 4.
HIF-1α Stabilization Induced by NO or Hypoxia.
Hypoxia-inducible factor-1 (HIF-1) is a transcription factor
composed of HIF-1α and HIF-1β subunits, which regulates
cellular response to oxygen. While HIF-1β is constitutively
expressed, HIF-1α protein levels are minimal or undetectable
under normoxic conditions. During hypoxia, HIF-1α protein is
stabilized and translocated to the nucleus where its
dimerization with HIF-1β leads to HIF-1 binding at hypoxia
responsive elements (HRE) in many target genes including
those involved in angiogenesis and cellular metabolism. In
cancer, HIF-1α dysregulation and/or overexpression promotes
tumor growth and metastasis by regulating tumor angiogenesis,
cellular metabolism, and survival in response to tumor hypoxia,
thus making HIF-1α an attractive chemotherapeutic target.43 It
is widely understood that normoxia regulates the protein
stability and turnover of HIF-1α, through hydroxylation of two
key proline residues (Pro402 and Pro564) by prolyl
hydroxylase (PHD), which targets HIF-1α for ubiquitination
and proteasomal degradation.44,45 Interestingly, S-nitrosation
by NO attenuates PHD activity and stabilizes HIF-1α protein
levels under normoxic conditions.13,46,47 With this in mind, we
examined the eﬀect of [Ru(bpy)2(SO3)(NO)]
+ complex on
NO- or hypoxia-induced HIF-1α protein stabilization in MB-
231 and MCF-7 breast cancer cells. Thomas et al. have shown
HIF-1α stabilization following exposure to the NO donor
SPER/NO (4 h).13 Pretreatment (30 min) of MB-231 breast
cancer cells with 10 μM [Ru(bpy)2(SO3)(NO)]
+ (1) abated
SPER/NO-induced HIF-1α stabilization as shown in Figure
5A,B. The control compound [Ru(bpy)(SO3)H2O] (2) did not
alter signiﬁcantly the level of SPER/NO induced HIF-1α (only
∼25%). Abated HIF-1α levels by HNO released from the
[Ru(bpy)2(SO3)(NO)]
+ complex are consistent with the
observations of Norris et al., who demonstrated that HNO
produced by Angeli’s salt also attenuated HIF-1α protein levels
in MB-231 and MCF-7 cells when compared to controls.12
Importantly, 10 μM [Ru(bpy)2(SO3)(NO)]
+ alone did not
induce HIF-1α stabilization (Figure 5A,B), indicating that
under these conditions [Ru(bpy)2(SO3)(NO)]
+ released HNO
but not NO. Interestingly, Figure 5C shows that SPER/NO-
induced HIF-1α stabilization was not eﬀected by YC-1 (3-(5′-
hydroxymethyl-2′-furyl)-1-benzyl indazole), a known Akt-
dependent inhibitor of hypoxia-induced HIF-1α.48 [Ru-
(bpy)2(SO3)(NO)]
+ also signiﬁcantly disrupted hypoxia-
induced HIF-1α (Figure 5D,E); however it was less eﬃcient
when compared to YC-1. Importantly, a functional in vitro
angiogenesis assay demonstrated a dramatic reduction in
endothelial tube formation by [Ru(bpy)2(SO3)(NO)]
+ as
shown in Figure 5F,G. Together these results provide evidence
of anti-HIF and antiangiogenic eﬀects by thiol-dependent
release of HNO from [Ru(bpy)2(SO3)(NO)]
+ applied in
biological systems.
■ DISCUSSION
Here, we have employed two diﬀerent probes, ferric-myoglobin
and carboxy-PTIO, to investigate production of HNO from
reactions of [Ru(bpy)2(SO3)(NO)]
+ (1) with thiols. These
reactions generated a species compatible with HNO as
indicated by the two detection methods (Figures 2 and 3).
Ferric myoglobin exhibited a typical lowering and red shift of
the Soret band along with the appearance of two bands in the
Q-band region, indicative of ferrous-NO myoglobin generation.
This behavior mirrored a control reaction using a known HNO
donor. Moreover, [Ru(bpy)2(SO3)(NO)]
+ did not react with
ferric-myoglobin at all, even upon light irradiation, unless thiols
were added. In addition, cPTIO provided additional evidence
of HNO production triggered by thiols as supported by the
Figure 4. Electrochemical response of [Ru(bpy)2(SO3)(NO)]
+ (1
mM) in reactions with glutathione in 0.1 M phosphate buﬀer at a pH
of 7.4, followed by square-wave voltammetry (glassy carbon as the
working electrode and Ag|AgCl as the reference electrode, reductive
sweep). (A) 10-fold molar excess of reduced glutathione (10 mM);
(B) 2-fold excess of glutathione (2 mM), monitored for 30 min.
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disappearance of its EPR signal. Interestingly, there was no
evidence of NO release using cPTIO as a probe, which did not
show an increase in the number of EPR lines. Indeed, such
behavior was observed only upon light irradiation of [Ru-
(bpy)2(SO3)(NO)]
+ (Supporting Information Figure S4),
which is known to photorelease NO.25 Our earlier quantitative
work suggested that NO is released upon reactions with
thiols.23 While minimal NO can still be produced, the present
work shows that HNO is clearly the main species generated and
the most likely product of thiol activation of such metal-
lonitrosyl complexes. Other investigators have also suggested
that reactions of metallonitrosyl complexes with thiols can lead
to alternative routes producing either NO or HNO.49
NMR results supported the production of oxidized
glutathione from reactions in a stoichiometry of 2:1 GSH/
Ru(bpy)2(SO3)(NO)]
+, consistent with a two-electron process
yielding NO−. Electrochemical data also showed evidence for
suppression of the reduction process assigned to NO+/0 as well
as for NO0/−, upon the addition of glutathione. Previous kinetic
studies showed spectroscopic evidence of an adduct,23 which
might release oxidized glutathione and give rise to Ru-HNO. It
is reasonable to assume modest release of HNO. Indeed, there
Figure 5. Limitation of HIF-1α stabilization by [Ru(bpy)2(SO3)(NO)]
+ (1) in breast cancer cells treated with 100 μM SPER/NO or under hypoxia.
(A) Western blot of HIF-1α and HPRT housekeeping control protein levels in MB-231 breast cancer cells pretreated with 10 μM 1 or
[Ru(bpy)2(SO3)(H2O)] control (2) for 30 min prior to HIF-1α stimulation (4 h) by the NO donor SPER/NO (100 μM). (B) Quantitative
measurement of HIF-1α normalized to HPRT in MB-231 cell lysates shown in A. (C) YC-1, a known inhibitor of hypoxia-induced HIF-1α fails to
block HIF-1α stabilization by SPER/NO. (D) Western blot of HIF-1α and HPRT housekeeping control in MCF-7 breast cancer cells ﬂushed with
N2 gas for 1.5 h to create hypoxic conditions. YC-1 is included as a positive control, which inhibits hypoxia induced HIF-1α protein accumulation.
(E) A quantitative measurement of HIF-1α normalized to HPRT shown in panel D. (F) Abated HUVEC tube formation in in vitro angiogenesis
assay along with (G) quantitative measurements of enclosed and partially enclosed networks in [Ru(bpy)2(SO3)(NO)]
+-treated cells versus control.
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are examples of reasonably stable metal complexes containing
HNO, such as [Fe(CN)5(HNO)]
3− where the extent of HNO
release is modest and quite slow (koff < 4.7 × 10
−7 s−1).50
[Ru(bpy)2(SO3)(H2O)] is assigned as one ﬁnal product from
the present reaction with thiols and shows intense band at 450
nm.23
Studies of a series of ruthenium nitrosyl complexes have
shown that [Ru(bpy)2(SO3)(NO)]
+ exhibits promising trypa-
nocidal activity against Trypanosoma cruzi by promoting higher
survival rates in infected mice.28 Additionally, this metal
complex inhibits T. cruzi GAPDH enzymatic activity, which is
thought to be its physiological target. The crystal structure of
GAPDH following the reaction with [Ru(bpy)2(SO3)(NO)]
+
suggested an NO-mediated thiol modiﬁcation.28 However, the
speciﬁc thiol modiﬁcation did not resemble S-nitrosylation, as
would be expected for an NO mechanism. In contrast, the
modiﬁcation was consistent with sulﬁnamide or sulﬁnic acid
adducts caused by HNO. Interestingly, one of the best-
described biological targets of HNO is indeed GAPDH, where
the thiol modiﬁcation generated a sulﬁnamide or sulﬁnic acid
moiety.8
Additionally, HIF-1α degradation promoted by HNO was
earlier thought to be associated with the direct eﬀect of HNO
on GADPH activity.12 This phenomenon is associated with a
fast reaction of HNO with a GADPH active cysteine residue
generating a sulfonamide modiﬁcation that culminated in the
disruption of glycolytic pathways.12 On the basis of this
evidence, it is reasonable to suggest the reduction of HIF-1α
protein could result from GADPH inhibition promoted by this
metal complex.
Herein, the chemical evidence for HNO generation from
[Ru(bpy)2(SO3)(NO)]
+ was validated biologically by the
demonstration of reduced HIF-1α protein accumulation in
cancer cells treated with NO or hypoxia. Similar eﬀects of
HNO produced by Angeli’s salt on abated HIF-1α accumu-
lation in cancer cells was shown earlier and is fully consistent
with our studies using a metallonitrosyl complex.12 As far as we
are aware, these results provide the ﬁrst biological evidence of
anticancer eﬀects of a metal complex acting as an HNO donor.
Vascularization is a very important process in physiological and
pathological conditions; its inhibition can be therapeutically
beneﬁcial in the treatment of cancer.52 Solid tumors grow at a
very fast rate and require increased neo-vascularization to
support the necessary supply of oxygen and nutrient require-
ments as well as metastatic processes. Blockade of this route
provides an opportunity to contain tumor growth and
metastatic disease. HIF-1α is a transcription factor essential
for regulating vascularization and VEGF expression, and it is
closely regulated by an oxygen-dependent prolyl hydroxylase.
Under normoxic conditions, prolyl hydroxylases modify HIF-
1α leading to proteasomal degradation, and low levels of HIF-
1α are maintained. On the other hand, in hypoxic tissue, this
post-transcriptional modiﬁcation is blocked, causing HIF-1α
accumulation, which then upregulates neo-vascularization
processes. Only a limited number of compounds that target
HIF are under development. Also, HNO and NO exhibit
divergent HIF-1α regulation; NO promotes HIF-1α stabiliza-
tion while HNO limits its accumulation. We exploited this
divergent behavior as a biological assay to investigate NO
versus HNO activity. Our results support the use of
[Ru(bpy)2(SO3)(NO)]
+ as a promising therapeutic agent for
abated HIF-1α accumulation. Under hypoxic conditions,
[Ru(bpy)2(SO3)(NO)]
+ reduced HIF-1α however less eﬀec-
tively when compared to YC-1. Moreover, [Ru(bpy)2(SO3)-
(NO)]+ dramatically reduced HIF-1α under conditions of
elevated NO. This is signiﬁcant because YC-1, a leading
compound used for the development of new antiangiogenic
agents, failed to reduce HIF stabilization induced by NO.
Importantly, elevated NOS2-derived NO predicts poor survival
in patients with aggressive tumors including estrogen receptor
negative breast cancer where NOS2 directly correlated with the
vascular marker CD31.53 In addition, high NOS2 expressing
tumors exhibited greater than 3-fold elevations in glutamate
cysteine ligase, which is the rate-limiting enzyme in the
glutathione synthesis pathway, which suggests that patients with
this NOS2 signature may beneﬁt from [Ru(bpy)2(SO3)(NO)]
+
or similar drugs.53
Conclusions. The elucidation of HNO biochemistry has led
to new discoveries with therapeutic potential, which warrants
the development of novel HNO donors. The current study
provides evidence that HNO is indeed generated by [Ru-
(bpy)2(SO3)(NO)]
+ upon reaction with thiols; such reactions
could be responsible for several of the biological activities
described for this compound so far. Moreover, this and other
structurally related compounds are novel HNO donors that are
candidate antiangiogenic agents with potential applications in
cardiovascular and cancer therapy. The current study
demonstrates that the reactivity of bound NO is essential for
HNO generation, which warrants further investigation as a new
generation of ruthenium nitrosyl complexes, with larger and
moderate NO+ character for improved thiol-reactive HNO
donors.
Potential applications for these ruthenium compounds
include anticancer therapy for aggressive breast tumors
expressing elevated NOS2 and increased glutamate cysteine
ligase, which would enhance tumor glutathione levels. In such
tumors, this compound might be quite suitable for therapy and
work also as a tool to modulate the levels of thiol-reactive
species. Multidrug resistance pathways utilize glutathione to
pump drugs out of the cell; HNO-based drugs may be
beneﬁcial in the treatment of these resistant tumor phenotypes
as well. HNO also aﬀects cellular glucose transport by
modulating GLUT1 activity as demonstrated using Angeli’s
salt.51 Collectively, these observations have stimulated interest
in new therapeutic opportunities for HNO donors, suggesting
that this molecule will attract increasing attention in years to
come.
■ METHODS
Mate r i a l s . N-[4 - [1 - ( 3 -Am inop ropy l ) - 2 - h yd ro x y - 2 -
nitrosohydrazino]butyl]-1,3-propanediamine (SPER/NO), diethyl-
amine NONOate diethylammonium salt (DEA-NO), sodium
trioxodinitrate (Angeli’s salt), 2-(4-carboxyphenyl)-4,4,5,5-tetramethy-
limidazoline-1-oxyl-3-oxide potassium salt (carboxy-PTIO, cPTIO),
ferric myoglobin (metMb, equine skeletal muscle), reduced gluta-
thione (GSH), oxidized glutathione (GSSG), ascorbic acid, N-acetyl-
cysteine (NAC), triﬂuoroacetic acid (HTFA), sodium sulphite,
bipyridine, ruthenium trichloride, sodium hydroxide, sodium nitrite,
Na2H2edta, Na2HPO4, and NaH2PO4 were purchased from Sigma-
Aldrich. Organic solvents were all of chromatographic grade. Water
used in the experiments and synthesis was ultrapuriﬁed using a Milli-Q
system (>18 MΩ cm). [Ru(bpy)2(SO3)(NO)](PF6) (1) was prepared
as described in the literature and [Ru(bpy)2(SO3)(H2O)] (2) as in ref
25.
Myoglobin As a Probe for HNO Production. To detect HNO
production, ferric-myoglobin at a 7−8 μM ﬁnal concentration in 0.1 M
phosphate buﬀer at a pH of 6.3 at 25 °C was employed. See the
Supporting Information for details.
ACS Chemical Biology Articles
DOI: 10.1021/acschembio.6b00222
ACS Chem. Biol. 2016, 11, 2057−2065
2062
Carboxy-PTIO Reaction to Identify HNO. Carboxy-PTIO was
used to probe HNO and NO formation as characterized by
characteristic changes in their UV−vis and EPR spectra. This organic
spin-trap was used at 100−200 μM in 0.1 M phosphate buﬀer at a pH
of 6.3 along with reduced gluthathione and N-acetyl-cysteine alone
and in reaction with [Ru(bpy)2(SO3)(NO)]
+ as well as upon light
irradiation. See the Supporting Information for details.
Hydroxylamine Detection. This measurement was conducted as
described elsewhere54 with minor modiﬁcations.55 See the Supporting
Information for details.
NMR Studies of Reactions of Ru Complex with Glutathione.
1H NMR spectra were recorded on a Bruker AV111−400
spectrometer for 7.2 mM solutions of [Ru(bpy)2(SO3)(NO)]
+ with
1 mol equiv of sodium azide, or 0.5, 1.0, or 2.0 mol equiv of
glutathione in phosphate buﬀer/D2O at a pH of 7.4 at 298 K.
Electrochemistry Measurements. Square-wave voltammetry was
used to measure the half-wave potential of 0.8 mM [Ru(bpy)2(SO3)-
(NO)]+, before and after the addition of reduced glutathione (1 mM
to 15 mM), in argon degassed 0.1 M phosphate buﬀer (pH 7.4) as an
electrolyte, at 298 K. These measurements were performed in an
electrochemical analyzer from Bioanalytical System Inc. (BAS) model
EPSILON, using a conventional electrochemical glass cell containing
three electrodes: glassy carbon as a working electrode, Ag|AgCl as a
reference electrode, and platinum foil as an auxiliary electrode.
HIF-1α Inhibition Assay. MCF-7 or MB-231 breast cancer cells
(2 × 106 cells) were plated into 60 mm cell culture dishes in RPMI
complete medium supplemented with 10% HI FBS and penicillin-
streptomycin and incubated overnight. The next day, the cells were
pretreated with the metallonitrosyl 1 [Ru(bpy)2(SO3)(NO)](PF6) or
control 2 compound ([Ru(bpy)2(SO3)(H2O)]) for 30 min in serum-
free medium, then treated with 100 μM SPER/NO for 4 h. See the
Supporting Information for details.
Automated Capillary Western Blot (WES). Western blots were
performed using WES, an automated capillary-based size sorting
system (ProteinSimple, San Jose CA).56 All procedures were
performed with the manufacturer’s reagents according to their user
manual. See the Supporting Information for details.
In Vitro Angiogenesis Assay. Antiangiogenic eﬀects were
examined using an in vitro angiogenesis assay kit (EMD Millipore,
Billerica MA) according to the manufacturer’s recommendations. See
the Supporting Information for details.
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